Cargando…
Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436
Autores principales: | Hu, Wen, Zhang, Li, Ferri-Borgogno, Sammy, Kwan, Suet-Ying, Lewis, Kelsey E., Cun, Han T., Yeung, Tsz-Lun, Soliman, Pamela T., Tarapore, Rohinton S., Allen, Joshua E., Guan, Xinyuan, Lu, Karen H., Mok, Samuel C., Au-Yeung, Chi-Lam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915108/ https://www.ncbi.nlm.nih.gov/pubmed/33557446 http://dx.doi.org/10.3390/cancers13040623 |
Ejemplares similares
-
Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype
por: Hu, Wen, et al.
Publicado: (2020) -
Ryanodine receptor 1-mediated Ca(2+) signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes
por: Zhang, Li, et al.
Publicado: (2022) -
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020) -
Imipridone family on successful TRAIL
por: Anderson, Peter M., et al.
Publicado: (2017) -
Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression
por: Kwan, Suet-Ying, et al.
Publicado: (2020)